LDL-C management: should it begin in the cathlab?

Sponsored by Amgen
Other coronary interventions
Symposium
Imaging
Amgen
Room 252A

Watch this session if you want

  • To discuss the latest evidence on PCSK9 inhibition in patients undergoing elective PCI and its implications for clinical practice
  • To assess current and emerging data supporting early and intensive LDL-C management in ACS
  • To examine how advanced imaging and artificial intelligence-enabled platforms, including HeartFlow, can enhance early risk stratification and optimise management of high-risk ASCVD

Suggested videos